Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
1010 HLA-B allele frequencies in immune checkpoint inhibitor-associated rheumatologic adverse events
- 135 Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- 2Baylor College of Medicine, Houston, TX, USA
- 3The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Related
- Immune Responses in Checkpoint Inhibitor–Associated Cardiovascular Immune–Related Adverse Events
- Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study.
- Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial
- Immune checkpoint inhibitor-associated interstitial nephritis: let’s move forward addressing the unknowns
- Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizumab and ursodeoxycholic acid
BibTeX
@article{wang20261010,
title = {{1010 HLA-B allele frequencies in immune checkpoint inhibitor-associated rheumatologic adverse events}},
author = {Yinghong Wang and Lily Xu and Yuanteng Jeff Li},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.1010},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.1010},
note = {CC BY},
}
RIS
TY - JOUR
TI - 1010 HLA-B allele frequencies in immune checkpoint inhibitor-associated rheumatologic adverse events
AU - Yinghong Wang
AU - Lily Xu
AU - Yuanteng Jeff Li
PY - 2026
DA - 2026/11/06
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.1010
UR - https://doi.org/10.1136/jitc-2026-sitc2026.1010
SN - 2051-1426
ER -